PATENT CLAIM ANALYSIS

Application Number: 15775202
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["514", "045000"]

Abstract:
The present invention relates to a composition comprising a first compound which is a nucleoside analogue capable of inhibiting a bacterial colonisation or infection of a subject; a second compound which is capable of decreasing mitochondrial toxicity of said nucleoside analogue and surprisingly enhance the antibacterial effect of the combination; and a third compound capable of decreasing the concentration in bacteria of nucleosides and/or nucleotides known to compete with nucleoside analogues. The first compound may be AZT, FdUrd, 5-fluorouracil, BrdUrd, IdUrd, didanosine or gemcitabine; the second compound may be uridine or a uridine-comprising compound; and the third compound may be trimethoprim or a compound comprising trimethoprim, such as trimethoprim-sulfa.

Claim (Index 18):
A pharmaceutical preparation according to  claim 17 , wherein the first compound is AZT, the second compound is uridine and the third compound is trimethoprim.

Metadata:
- Claim Count in Document: 65.0
- Percentile: 93.0
- Lexical Diversity: 1.92063
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['08460186', '15380648', '11891629', '12842412', '09925824']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7248154343155384
- 35 USC 102 Novelty (BERT): 0.5024972117423753
- Combined Prediction Score: 0.7025836120582222
- Mean Citation Score: 189.474594
- Max Citation Score: 207.34462
- Similarity Product: 141.79265346594096

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test